Movement Alert|Roivant Sciences Ltd. Intraday Rise 5.41%, Fiscal Q2 Revenue Beat and Pipeline Progress Support Sentiment

Market Focus11-09

On November 9, Roivant Sciences Ltd. rose 5.41% in Regular Trading, trading at $40.625 per share, with turnover of $28.1903 million.

The move followed the company’s fiscal Q2 results and recent pipeline updates, which together improved market sentiment.

For the quarter ended September 30, Roivant Sciences Ltd. reported a net loss of $0.27 per diluted share, wider than $0.17 a year earlier but slightly better than the $0.28 loss expected by the analyst tracked by FactSet. Revenue rose to $35.1 million from $1.6 million a year earlier, far above the $4.3 million consensus expectation, while cash, cash equivalents, restricted cash and marketable securities totaled $4.20 billion.

Recent development milestones also added support: brepocitinib achieved primary and key secondary endpoints in two phase 3 non-infectious uveitis trials; mosliciguat met primary and secondary endpoints in a phase 2 PH-ILD study and advanced into phase 3 development; and brepocitinib was approved in August for adult dermatomyositis and launched in the US.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment